Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Meyenburg Prize 2019 for outstanding research on leukemia

No. 51 | 06/11/2019 | by Koh

The Meyenburg Prize 2019, which carries prize money of 50,000 euros, goes to Benjamin L. Ebert from the Dana-Farber Cancer Institute in Boston for his outstanding research results on the pathogenesis and treatment of leukemia. The award ceremony will take place on Thursday, November 7, 2019 as part of a symposium at the German Cancer Research Center.

Benjamin L. Ebert (left), Stefan Fröhling (Managing Director of NCT Heidelberg)
© Carina Kircher/DKFZ

"Benjamin Ebert is a highly creative and multifaceted scientist. His work has led to important new findings in various areas of cancer research that have made a crucial contribution to improving our understanding of cancer. His research results also have a direct impact on diagnosis and treatment," explained Stefan Fröhling, Director of the Meyenburg Foundation and Managing Director of NCT Heidelberg. "The Meyenburg Prize 2019 recognizes Benjamin Ebert's outstanding contribution to improving clinical care for cancer patients through high-quality research."

One of the results from Ebert's laboratory that has attracted the most attention was the identification of genetic mutations in blood and bone marrow cells that predispose older people to developing leukemia. Individuals with this "pre-malignant syndrome" do not meet the criteria for a diagnosis of leukemia, even though the same mutations occur in leukemia patients, as discovered by Ebert and his colleagues from the genome data of tens of thousands of people. People with this "CHIP syndrome" have a tenfold higher risk of developing leukemia than the general population; they also have a considerably higher overall mortality rate and, to the researchers' surprise, a higher risk of cardiovascular diseases. Patients who have been diagnosed as having CHIP can now be closely monitored for leukemia to allow treatment to be started as early as possible.

Benjamin Ebert also revealed the mode of action of an important cancer drug: Lenalidomide, which is related to thalidomide, is effective against certain types of multiple myeloma. Along with related drugs, the substance leads to degradation of certain cancer-promoting transcription factors in cells, which in turn reduces cancer growth. These findings were the starting point for a completely new area of research in which huge efforts are now being undertaken to develop drugs that are able to degrade cancer-promoting proteins.

Benjamin L. Ebert
© Carina Kircher/DKFZ

Benjamin L. Ebert obtained a bachelor's degree from Williams College, Massachusetts, a doctorate from Oxford University, and an M.D. from Harvard Medical School. He completed a residency at Massachusetts General Hospital and a fellowship in hematology/oncology at the Dana-Farber Cancer Institute. He worked at Brigham and Women's Hospital at Harvard Medical School for ten years before being appointed to the Chair of Medical Oncology at the Dana-Farber Cancer Institute.

Benjamin L. Ebert has received a number of awards and accolades, including most recently his election to the U.S. National Academy of Medicine, the William Dameshek Prize from the American Society of Hematology, and the McCulloch & Till Award from the International Society for Experimental Hematology.

Based at the German Cancer Research Center, the Meyenburg Foundation has been awarding the prize since 1981. Dr Marion Meyenburg, the daughter of the founders Wilhelm and Maria Meyenburg, will be presenting this year's prize in person at the end of the symposium. The prize is awarded annually for outstanding achievements in the field of cancer research and is one of Germany's science awards with the highest prize money. The importance of the award can also be seen from the fact that many of the researchers who have won the Meyenburg Prize are also Nobel laureates: Andrew Fire, winner of the Meyenburg Prize 2002, was awarded the Nobel Prize for Medicine in 2006; Elizabeth Blackburn, winner of the Meyenburg Prize 2006, was awarded the Nobel Prize for Medicine in 2009; Shinya Yamanaka, winner of the Meyenburg Prize 2007, was also awarded the Nobel Prize for Medicine in 2012; Stefan Hell, winner of the Meyenburg Prize 2011, won the Nobel Prize for Chemistry in 2014.

In addition to Benjamin Ebert, the speakers at the Meyenburg Symposium 2019 will be Hartmut Döhner (Ulm University Hospital), Richard Rosenquist Brandell (Karolinska Institute, Stockholm), Rocio Sotillo (DKFZ), and Winette van der Graaf (Netherlands Cancer Institute, Amsterdam). The event will be held at DKFZ's Communication Center from 3.30 pm on Thursday, November 7, 2019. The symposium and award ceremony are open to anyone interested in the event.

*CHIP: clonal hematopoiesis of indeterminate potential

The program is available for downloading: 


With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS